Bestaande gebruiker? Log in
Abonneren
Home
Beurs vandaag
Koersen
Nieuws
Agenda
Analisten
Analisten vandaag
Meest aanbevolen aandelen
Minst aanbevolen aandelen
Aandelen met grootste potentieel
Insider trading
Insiders vandaag
Meest gekochte aandelen
Meest verkochte aandelen
Mijn Trivano
Mijn Trivano
Mijn selecties
Mijn nieuwsbrieven
Abonneren
Beurs vandaag
Koersen
Nieuws
Agenda
Analisten
Insider trading
Mijn Trivano
Registreren / inloggen
Beurs vandaag
Amerika
Vanda Pharmaceuticals Inc
Nieuws
Vanda Pharmaceuticals Inc
VNDA
NAS
: VNDA
| ISIN: US9216591084
19:01
4,160 USD
(+6,94%)
(+6,94%)
19:01
Aandeel volgen
Aandeel gevolgd
Samenvatting
Nieuws
Insiders
Technische analyse
TA
Toon enkel gratis nieuws
6 maart 2024 ·
Vanda Pharmaceuticals Announces FDA Update for supplemental NDA for HETLIOZ® in the Treatment of Insomnia
· Persbericht
7 februari 2024 ·
Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results
· Persbericht
5 februari 2024 ·
Vanda Pharmaceuticals Announces FDA Update for supplemental NDA for HETLIOZ® in the Treatment of Insomnia
· Persbericht
31 januari 2024 ·
Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2023 Financial Results on February 7, 2024
· Persbericht
31 januari 2024 ·
Vanda Pharmaceuticals Receives FDA Approval to Proceed with Investigational New Drug VTR-297 a Topical Antifungal Candidate for the Treatment of Onychomycosis
· Persbericht
30 januari 2024 ·
Court Orders FDA to Resolve Vanda Pharmaceuticals' Jet Lag Hearing Request by March 5, 2024
· Persbericht
30 januari 2024 ·
Court Orders FDA to Resolve Vanda Pharmaceuticals' Jet Lag Hearing Request by March 5, 2024
· Persbericht
26 januari 2024 ·
Vanda Pharmaceuticals Announces a U.S. Patent Allowance for PONVORY® (ponesimod) in the U.S.
· Persbericht
25 januari 2024 ·
Vanda Pharmaceuticals announces the publication of an article on "The Efficacy of Tradipitant in Patients with Diabetic and Idiopathic Gastroparesis in Phase III Randomized Placebo-Controlled Clinical Trial" in the Clinical Gastroenterology and Hepatology Journal
· Persbericht
23 januari 2024 ·
Vanda Pharmaceuticals Receives FDA Approval to Proceed with Investigational New Drug VCA-894A, a Novel Antisense Oligonucleotide Candidate for the Treatment of Charcot-Marie-Tooth Disease, Type 2S
· Persbericht
19 januari 2024 ·
Federal Court Allows Vanda Pharmaceuticals' Lawsuit to Proceed Against the U.S. Food and Drug Administration
· Persbericht
17 januari 2024 ·
Vanda Pharmaceuticals announces the publication of Efficacy and Safety of Iloperidone in Bipolar Mania: A Double-Blind, Placebo-Controlled Study in the Journal of Clinical Psychiatry
· Persbericht
12 januari 2024 ·
Vanda Pharmaceuticals Comments on FDA's Recently Announced Guidance on Communication with Health Care Professionals Regarding FDA-Approved Drugs
· Persbericht
4 januari 2024 ·
Vanda Pharmaceuticals Announces Participation in the J.P. Morgan Healthcare Conference
· Persbericht
7 december 2023 ·
Vanda Pharmaceuticals Acquires U.S. and Canadian Rights to PONVORY® (ponesimod), a Selective S1P1R Modulator Approved for Patients with Relapsing Multiple Sclerosis
· Persbericht
5 december 2023 ·
Vanda Pharmaceuticals Announces that U.S. Food and Drug Administration Accepts New Drug Application for Tradipitant for the Treatment of Gastroparesis
· Persbericht
9 november 2023 ·
Vanda Pharmaceuticals Announces Participation at November 2023 Investor Conferences
· Persbericht
8 november 2023 ·
Vanda Pharmaceuticals Reports Third Quarter 2023 Financial Results
· Persbericht
1 november 2023 ·
Vanda Pharmaceuticals to Announce Third Quarter 2023 Financial Results on November 8, 2023
· Persbericht
20 oktober 2023 ·
Vanda Pharmaceuticals Intends to Petition the U.S. Supreme Court in its HETLIOZ® ANDA Litigation
· Persbericht
Aandeel volgen
Aandeel gevolgd
Mijn selecties
Voorbeeldselectie
Je selectie is nog leeg.
Voeg nu effecten toe